PAHCQT52Phibro Animal Health Corporation·NASDAQ
38.88+0.05%
TA
Loading chart...
Signal & projected range
QT Score upgradeHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E15.93EPS (ttm)2.44Insider Own—Shs Outstand40.60MPerf Week0.21%
Market Cap1.58BForward P/E10.10EPS next Y3.85Insider Trans-0.02%Shs Float40.30MPerf Month8.39%
Enterprise Value2.27BPEG1.42EPS next Q0.78Short Float2.56%Perf Quarter4.66%
Income100.00MP/S1.04EPS this Y13.75%Short Ratio4.54Perf Half Y-29.17%
Sales1.52BP/B4.10EPS next Y10.07%ROA6.64%Short Interest1.03MPerf YTD4.07%
Book/sh9.48P/C19.25EPS next 5Y11.21%ROE28.67%52W High60.08 -35.29%Perf Year-5.61%
Cash/sh2.02P/FCF175.40EPS past 3/5Y44.42% 12.73%ROIC11.81%52W Low28.25 37.63%Perf 3Y259.00%
Dividend Est.0.48 (1.23%)EV/EBITDA9.60Sales past 3/5Y15.78% 12.75%Gross Margin33.71%Volatility2.53% 3.47%Perf 5Y72.42%
Dividend TTM0.48 (1.23%)EV/Sales1.50EPS Y/Y TTM106.78%Oper. Margin13.07%ATR (14)1.31Perf 10Y51.11%
Dividend Ex-DateSep 02, 2026Quick Ratio1.27Sales Y/Y TTM17.21%Profit Margin6.57%RSI (14)56.91Recom2.86
Dividend Gr. 3/5Y0.00% 0.00%Current Ratio2.96EPS Q/Q49.12%SMA201.62%Beta0.42Target Price28.00
Payout19.52%Debt/Eq2.02Sales Q/Q4.75%SMA505.10%Rel Volume0.84Prev Close38.86
Employees2,605LT Debt/Eq1.96EarningsNov 04SMA200-5.77%Avg Volume218.73KPrice38.88
IPO DateApr 11, 2014Option/ShortYes / YesEPS/Sales Surpr.19.25% 4.07%Net Debt/EBITDA2.94Volume182,782Change0.05%
Analyst Ratings
DateActionAnalystRatingTarget
Feb-06-26ReiteratedMorgan StanleyEqual Weight$45 → $49
Aug-28-25ReiteratedMorgan StanleyEqual Weight$26 → $34
Jul-07-25UpgradeJP MorganNeutral → Overweight
Jun-25-25ReiteratedMorgan StanleyEqual Weight$20 → $26
Apr-15-25ReiteratedMorgan StanleyEqual Weight$27 → $20
Dec-21-22ReiteratedRoth CapitalBuy$18
Sep-16-22ReiteratedBarclaysUnderweight$17
Aug-26-22ReiteratedMorgan StanleyEqual Weight$21
Jul-25-22DowngradeBarclaysEqual Weight → Underweight
Jan-10-22UpgradeBarclaysUnderweight → Equal Weight
Latest News· Times ET
Oct-29-26
Oct-28-26
Oct-23-26
Oct-22-26
Oct-21-26
Oct-16-26
Oct-14-26
Oct-07-26
Oct-05-26
Oct-01-26
Sep-29-26
Sep-23-26
Sep-21-26
Sep-18-26
Sep-17-26
Company

Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2026
6/30/2026
FY 2025
6/30/2025
FY 2024
6/30/2024
FY 2023
6/30/2023
FY 2022
6/30/2022
FY 2021
6/30/2021
FY 2020
6/30/2020
FY 2019
6/30/2019
Total Revenue1,5191,5181,2961,018—————
Cost of Goods Sold Incl. D&A1,0051,006896705—————
Gross Profit512512400313—————
Selling, General and Administrative Excl. Other312313289260—————
Research and Development
0000—————
Other Operating Expense
0000—————
Operating Income19819811053—————
Interest Expense47483322—————
Unusual Expense
—————————
Non-Operating Income (Expense)-14-13-9-20—————
Net Income Before Taxes1361376811—————
Income Taxes3838209—————
Consolidated Net Income100100482—————
Net Income From Continuing Operations100100482—————
Net Income100100482—————
EPS (Recurring)2.462.461.190.06—————
EPS (Basic, Before Extraordinaries)2.462.461.190.06—————
EPS (Diluted)2.442.441.190.06—————
EBITDA23723614769—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio15.9312.8721.46279.50—————
Price To Sales Ratio1.050.850.810.68—————
Gross Margin33.7133.7330.8630.75—————
Operating Margin13.0313.048.495.21—————
Net Margin6.586.593.700.20—————
Shares Outstanding41414141—————
Market Capitalization1,5941,2871,047688—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$64.24$54.14$44.05$33.96$23.86● Close Price0.00M3.05M6.10M9.14M12.19MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
CORCORAN E THOMASDirectorMay 29 '26Buy31.7710,000317,70041,459Jun 02
BENDHEIM JACKPresident and CEOMay 07 '26Sale48.494,528219,56856,152May 07
BENDHEIM JACKPresident and CEOMay 06 '26Sale57.377,040403,85060,680May 07
BENDHEIM JACKPresident and CEOMay 05 '26Sale55.807,040392,81067,720May 07
BENDHEIM JACKPresident and CEOApr 30 '26Sale52.767,040371,46674,760Apr 30
BENDHEIM JACKPresident and CEOApr 29 '26Sale52.927,040372,55281,800Apr 30
BENDHEIM JACKPresident and CEOApr 28 '26Sale55.917,040393,57688,840Apr 30
BENDHEIM JACKPresident and CEOApr 23 '26Sale54.097,040380,82695,880Apr 23
BENDHEIM JACKPresident and CEOApr 22 '26Sale54.297,040382,185102,920Apr 23
BENDHEIM JACKPresident and CEOApr 21 '26Sale55.987,040394,081109,960Apr 23
BENDHEIM JACKPresident and CEOApr 16 '26Sale54.647,040384,661117,000Apr 16
BENDHEIM JACKPresident and CEOApr 15 '26Sale56.967,040401,01124,040Apr 16
BENDHEIM JACKPresident and CEOApr 14 '26Sale59.087,040415,92231,080Apr 16
BENDHEIM JACKPresident and CEOMar 31 '26Sale53.907,040379,42838,120Mar 31
BENDHEIM JACKPresident and CEOMar 30 '26Sale53.617,040377,40645,160Mar 31
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.